Quantitative analyses reveal substantial differences between Ofatumumab (OFA) and Rituximab (RTX) in mediating Complement-Dependent Cytotoxicity (CDC) of B cell lines and Chronic Lymphocytic Leukemia (CLL) cells

被引：0
|
作者：
Taylor, P. [1 ]
机构：
[1] Univ Virginia, Sch Med, Charlottesville, VA 22908 USA
来源：
MOLECULAR IMMUNOLOGY | 2011年 / 48卷 / 14期
关键词：
D O I：
10.1016/j.molimm.2011.06.366
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：1711 / 1712
页数：2
相关论文
共 10 条
  • [1] Binding of Submaximal C1q Promotes Complement-Dependent Cytotoxicity (CDC) of B Cells Opsonized with Anti-CD20 mAbs Ofatumumab (OFA) or Rituximab (RTX): Considerably Higher Levels of CDC Are Induced by OFA than by RTX
    Pawluczkowycz, Andrew W.
    Beurskens, Frank J.
    Beum, Paul V.
    Lindorfer, Margaret A.
    van de Winkel, Jan G. J.
    Parren, Paul W. H. I.
    Taylor, Ronald P.
    JOURNAL OF IMMUNOLOGY, 2009, 183 (01): : 749 - 758
  • [2] Binding of Submaximal C1q to B Cells Opsonized with Anti-CD20 Mabs Ofatumumab (OFA) or Rituximab (RTX) Promotes Complement Dependent Cytotoxicity (CDC), and Considerably Higher Levels of CDC Are Induced by OFA Than by RTX
    Taylor, Ronald P.
    Pawhiczkowycz, Andrew W.
    Lindorfer, Margaret A.
    de Winkel, Jan G. J. van
    Beurskens, Frank J.
    Parren, Paul W. H. I.
    BLOOD, 2008, 112 (11) : 560 - 560
  • [3] Induced Resistance to Ofatumumab-Mediated Cell Clearance Mechanisms, Including Complement-Dependent Cytotoxicity, in Chronic Lymphocytic Leukemia
    Baig, Nisar A.
    Taylor, Ronald P.
    Lindorfer, Margaret A.
    Church, Amy K.
    LaPlant, Betsy R.
    Pettinger, Adam M.
    Shanafelt, Tait D.
    Nowakowski, Grzegorz S.
    Zent, Clive S.
    JOURNAL OF IMMUNOLOGY, 2014, 192 (04): : 1620 - 1629
  • [4] rILYd4, a Human CD59 Inhibitor, Enhances Complement-Dependent Cytotoxicity of Ofatumumab against Rituximab-Resistant B-cell Lymphoma Cells and Chronic Lymphocytic Leukemia
    Ge, Xiaowen
    Wu, Lin
    Hu, Weiguo
    Fernandes, Stacey
    Wang, Chun
    Li, Xu
    Brown, Jennifer R.
    Qin, Xuebin
    CLINICAL CANCER RESEARCH, 2011, 17 (21) : 6702 - 6711
  • [5] Complement factor H-derived short consensus repeat 18-20 enhanced complement-dependent cytotoxicity of ofatumumab on chronic lymphocytic leukemia cells
    Hoerl, Susanne
    Banki, Zoltan
    Huber, Georg
    Ejaz, Asim
    Muellauer, Brigitte
    Willenbacher, Ella
    Steurer, Michael
    Stoiber, Heribert
    HAEMATOLOGICA, 2013, 98 (12) : 1939 - 1947
  • [6] Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells
    Lindorfer, Margaret A.
    Cook, Erika M.
    Tupitza, Jillian C.
    Zent, Clive S.
    Burack, Richard
    de Jong, Rob N.
    Beurskens, Frank J.
    Schuurman, Janine
    Parren, Paul W. H. I.
    Taylor, Ronald P.
    MOLECULAR IMMUNOLOGY, 2016, 70 : 13 - 23
  • [7] Complement-dependent cytotoxicity exerted by two therapeutic anti-CD20 mAbs: Rituximab and ofatumumab in human B-cell malignant cell lines and primary cultures
    Okroj, M.
    Eriksson, I.
    Osterborg, A.
    Blom, A.
    MOLECULAR IMMUNOLOGY, 2013, 56 (03) : 292 - 292
  • [8] Direct and complement dependent cytotoxicity in CLL cells from patients with high-risk early-intermediate stage chronic lymphocytic leukemia (CLL) treated with alemtuzumab and rituximab
    Zent, Clive S.
    Secreto, Charla R.
    LaPlant, Betsy R.
    Bone, Nancy D.
    Call, Timothy G.
    Shanafelt, Tait D.
    Jelinek, Diane F.
    Tschumper, Renee C.
    Kay, Neil E.
    LEUKEMIA RESEARCH, 2008, 32 (12) : 1849 - 1856
  • [9] Enhanced CDC of B cell chronic lymphocytic leukemia cells mediated by rituximab combined with a novel anti-complement factor H antibody
    Winkler, Mark T.
    Bushey, Ryan T.
    Gottlin, Elizabeth B.
    Campa, Michael J.
    Guadalupe, Eross S.
    Volkheimer, Alicia D.
    Weinberg, J. Brice
    Patz, Edward F., Jr.
    PLOS ONE, 2017, 12 (06):
  • [10] Treatment of chronic lymphocytic leukemia (CLL) patients with rituximab (RTX) depletes complement (C) and induces selective loss of B cell-bound CD20/RTX immune complexes: Evidence for removal of these immune complexes by the mononuclear phagocytic system.
    Taylor, RP
    Kennedy, AD
    Beum, PV
    Lindorfer, MA
    DiLillo, DJ
    Hess, CE
    Densmore, JJ
    Williams, ME
    BLOOD, 2003, 102 (11) : 110A - 110A
1